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ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not “Is the use
of a sustained-release intracanalicular dexamethasone depot an effective treatment for pain
reduction following cataract surgery?”
Study Design: A systematic review of three randomized controlled trials (RCTs) all published
between 2015 and 2019.
Data Sources: Two RCTs were discovered using PubMed, and one RCT was discovered using
Semantic Scholar. The articles were published in peer-reviewed journals in the English language
and selected based on relevance to the clinical question.
Outcome Measured: Absence of pain at day 8 following cataract surgery was a primary
outcome measured in all three studies using the Ocular Pain Assessment Scale. Patient-rated pain
scores ranged 0-10 with higher scores representing severe, disabling pain.
Results: All three studies found that intracanalicular dexamethasone depots provide a significant
reduction of ocular pain in patients following cataract surgery compared to the control group.
The RCT conducted by Walters et al. (2016) found a NNT of three and a calculated p-value of <
0.0001. This study was found to have a large treatment effect and is statistically significant. The
RCT led by Tyson et al. (2019) found a NNT of six and p-value of < 0.0001. This study was
found to have a large treatment effect and is statistically significant. Lastly, the RCT led by
Walters et al. (2015) found a NNT of three and p-value of < 0.0001. This study was found to
have a large treatment effect and is statistically significant. Additionally, in all three studies,
patients receiving intracanalicular dexamethasone required the use of additional antiinflammatory rescue drops far less than patients in the placebo group.
Conclusion: All three studies in this review demonstrated that the use of intracanalicular
dexamethasone depots provides a statistically significant reduction of pain severity following
cataract surgery. This suggests that it is an effective and advantageous treatment method for
post-cataract surgery ocular pain.
Key Words: Dexamethasone, cataract surgery, intracanalicular
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INTRODUCTION:
Cataracts are defined as an ocular condition in which the lens of the eye gradually
becomes opacified.1 Patients with visually significant cataracts suffer from blurred vision,
difficulty seeing in dim light, seeing halos around lights, vision loss, or total blindness.1
Cataracts are most commonly developed as a result of the natural aging process.1 Over time,
protein begins to accumulate and clump together in the lens. This gives the lens a cloudy
appearance and hinders light from passing through to the retina clearly. Cataracts can also be
acquired as a result of congenital abnormalities, systemic disease, medications, or trauma.1
Cataracts are the most common cause of blindness worldwide and the most common
cause of vision loss in the US.2 The number of patients needing cataract surgery is increasing
yearly due to our aging population.2 In the United States alone, cataracts affect approximately 22
million people over the age of 40.1 While there is an estimated $6.8 billion in direct medical
costs for the treatment of cataracts annually, an exact estimate for healthcare visit costs as a
result of this condition is unknown. However, it is known that in the United States, nearly 1.5
million people have cataract surgery annually.1
Topical steroid and topical NSAID medications are typically used for prophylactic
treatment of postoperative pain and inflammation that may follow cataract surgery.2-4 However,
patient compliance is oftentimes suboptimal for various reasons, and proper instillation
techniques are frequently lacking with the use of topical agents. 2-4 Patients, particularly the
elderly, often fail to remember to take the drops as scheduled due to a complex, tapered dosing
regimen.2,3 Patients also struggle with properly instilling the drops as the bottles the medications
are dispensed in can be difficult for them to handle.2,3 These factors negatively affect the efficacy
of the drug and can potentially put patients at increased risk for developing postoperative
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complications.2-4 A study was conducted where investigators asked cataract surgery patients to
self-administer antibiotic and steroid drops five times per day for two weeks. It was discovered
that only half of the patients were compliant with the medication schedule.5 The one-time
administration of sustained-release intracanalicular dexamethasone depots may be used as an
option to eradicate the concerns of patient compliance and inaccurate drop administration,
subsequently leading to enhanced efficacy of the drug’s ability to reduce postoperative pain and
complications following cataract surgery.
This paper evaluates three randomized control trials assessing the efficacy of sustainedrelease intracanalicular dexamethasone depots in the treatment of pain reduction following
cataract surgery. In all three studies, the dexamethasone as well as placebo was suspended in a
dried polyethylene glycol (PEG) hydrogel device and placed in the inferior canaliculus.5-7 The
rod shaped device was designed to expand once in contact with fluid from the ocular surface so
that it may stay securely placed inside the punctum.5-7 For up to 30 days, the depot releases a
sustained and tapered dose of preservative free dexamethasone or placebo to the ocular surface.57

The device then gradually liquifies, and dissipates through the nasolacrimal duct.5-7 Each

device was conjugated with fluorescein dye for the purpose of visualization and confirmation of
correct placement of the depot when viewed through a slit lamp.5-7
Previous studies have been conducted using hydrogel sustained-release depots. The
Singapore National Eye Center conducted a study evaluating the efficacy of moxifloxacin in a
hydrogel sustained-release depot.6 There have also been studies conducted in canines evaluating
the efficacy of travoprost as well as dexamethasone when suspended in a hydrogel sustainedrelease depot.6 Each of these previous studies support this method of delivering medications to
the ocular surface as being exceptionally efficacious.6
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OBJECTIVE:
The objective of this systematic EBM review is to determine “Is the use of a sustainedrelease intracanalicular dexamethasone depot an effective treatment for pain reduction following
cataract surgery?”
METHODS:
The population targeted in this selective EBM review were patients undergoing cataract
surgery. The intervention used in each study was a sustained-release dexamethasone depot
placed in the canaliculus of the operated eye. The comparison used in each study was a similarappearing placebo depot placed in the canaliculus of the operated eye. The outcome measured
that is being examined in this review is the absence of pain in the operated eye at day 8.
Studies were selected based on relevance and ability to answer the clinical question: “Is
the use of a sustained-release intracanalicular dexamethasone depot an effective treatment for
pain reduction following cataract surgery?”. Furthermore, articles were chosen if they contained
patient-oriented outcomes (POEMS) and fulfilled criteria based on intervention, comparison, and
outcome measured. It was required that all articles conducted randomized, placebo-controlled
clinical trials on patients undergoing cataract surgery without current ocular disease and using
intracanalicular dexamethasone depots for post-op ocular pain. The studies selected for this
review were found on PubMed and Semantic Scholar using keywords “cataract surgery”,
“intracanalicular”, and “dexamethasone”. In order for the articles to be selected, they must have
been published in peer-reviewed journals in the English language after 2010. Studies also must
have been randomized controlled trials and conducted on humans. Articles that were not
randomized, not published in a peer-reviewed journal, secondary studies, or published prior to
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2010 were excluded. Statistics reported in this review include Experimental Event Rate (EER),
Control Event Rate (CER), Relative Benefit Increase (RBI), Absolute Benefit Increase (ABI),
Number Needed to Treat (NNT), and p-values derived from patient-rated Ocular Pain
Assessment Scores. Demographics and characteristics of each study are included below in Table
1.
OUTCOME MEASURED:
The outcome measured in this review is the absence of ocular pain at day 8 following
cataract surgery.5-7 All three studies utilized patient-rated Numeric Ocular Pain Assessment
Rating Scales where 0 = no pain, 1 to 3 = mild pain (nagging, annoying, minimally interferes
with ADLs), 4 to 6 = moderate pain (significantly interferes with ADLs), and 7 to 10 = severe
pain (disabling, unable to perform ADLs).5-7 Patients completed the one question assessment
pertaining to their pain level at each follow up visit in the presence of a study investigator.5-7
Table 1. Demographics & Characteristics of Included Studies
Study

Type

Walters6
(2015)

RCT

#
Pts
60

Age
(yrs)
21+
years
old

Inclusion
Criteria
Cataractous lens
undergoing clear
corneal cataract
surgery with
phacoemulsification
and implantation of
PCIOL, potential
post-op pin-hole
Snellen visual acuity
> 20/200 in
operative eye, and >
20/200 in the fellow
eye

Exclusion
Criteria
Intraocular
inflammation, score
> 0 on the Ocular
Pain Assessment,
compromised
immune system, or
autoimmune disease,
obstructed
nasolacrimal duct

W/D
2

Interventions
0.4mg
intracanalicular
dexamethasone
insert vs.
intracanalicular
placebo insert,
both suspended
in a dried
polyethylene
glycol (PEG)based hydrogel
device
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Walters5
(2016)

RCT

247

18+
years
old

Tyson7
(2019)

RCT

438

18+
years
old

Visually significant
cataract with plans
to undergo clear
corneal cataract
surgery with
phacoemulsification
and PCIOL,
potential post-op
pinhole corrects
Snellen visual acuity
> 20/200 in both
eyes
Presence of a
cataract with plans
to undergo clear
corneal cataract
surgery with
phacoemulsification
and PCIOL,
potential post-op
Snellen pin-hole
CDVA > 20/200 in
both eyes

Intraocular
inflammation, score
> 0 on Ocular Pain
Assessment,
inflammatory eye
disease, significant
macular pathology,
glaucoma, ocular
HTN, corneal or
retinal surgery in
past 6 months

3

Intraocular
3
inflammation, score
> 0 on Ocular Pain
Assessment, diabetic
retinopathy,
significant macular
pathology, certain
ocular surgeries or
procedures during
study period or in
prior 6 months,
glaucoma, or ocular
HTN

0.4mg
intracanalicular
dexamethasone
insert vs.
intracanalicular
placebo insert,
both suspended
in a dried
polyethylene
glycol (PEG)based hydrogel
device
0.4mg
intracanalicular
dexamethasone
insert vs.
intracanalicular
placebo insert,
both suspended
in a dried
polyethylene
glycol (PEG)based hydrogel
device

RESULTS:
Walters et al.6 (2015) conducted a randomized double-blind RCT for a total of 30 days to
assess the efficacy and safety of dexamethasone as a biodegradable sustained-release depot when
placed in the canaliculus for the treatment of ocular pain in cataract surgery patients. A total of
60 individuals aged 21 and older, who were undergoing clear corneal cataract surgery with
phacoemulsification and implantation of a posterior chamber intraocular lens (PCIOL) were
selected to participate in the study across four sites in the US.6 Participants were selected
according to certain inclusion and exclusion criteria noted in Table 1. Participants were
randomized 1:1 to either receive 0.4 mg of preservative free sustained-release dexamethasone
suspended in a PEG-based hydrogel device, or an identical-appearing placebo vehicle device
inserted intraoperatively into the inferior distal canaliculus of the operated eye.6 Patients
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experiencing moderate to severe pain (pain score > 4) after surgery were allowed the use of
additional anti-inflammatory (rescue) drops.6 Patients who used rescue medication before the
primary endpoint of day 8 were considered treatment failures.6 The treatment groups consisted of
30 patients each. There was one patient who was not treated from the intervention group for
unknown reasons, so data from 59 patients was used in the statistical analysis.
There were two primary outcomes studied in this RCT though, the outcome being
analyzed in this review is the absence of ocular pain 8 days after cataract surgery.6 Ocular pain
severity was assessed using the Ocular Pain Assessment Scale. Patients rated their pain on a
scale 0-10, where 0 represented no pain, and 10 represented severe pain. Of the participants
receiving sustained-release dexamethasone, 79.3% of the patients were pain free compared to
30% in the placebo group at day 8 (Table 2).6 The difference between the two groups was 49.3%
(Table 2).6 Additionally, a significantly lower proportion of patients in the sustained-release
dexamethasone group compared to the placebo group received rescue medication at day 8.6 Of
29 patients, 5 (17.2%) patients in the intervention group received rescue medication compared to
16 (55.2%) out of 29 in the placebo group.6 Using dichotomous data from the study, a NNT of
three was calculated (Table 5), meaning that for every three cataract surgery patients receiving a
sustained-release dexamethasone depot, ocular pain for one more patient will be prevented
compared to the placebo. The study reported a p-value of < 0.0001 between the intervention and
control groups (Table 2).6 80% and 95% confidence intervals were constructed around the
difference in proportions for the outcome.6 Given the reported p-value and a low NNT, it can be
concluded that there is a large treatment effect that is statistically significant. Resultant values
from this study are shown below in Tables 2 and 5.

MONTGOMERY INTRACANALICULAR DEXAMETHASONE 7
Table 2. Occurrence of Ocular Pain in Walters et al.6 (2015) Study at day 8
Sustained-release
dexamethasone (n=29)
23 (79.3%)

Placebo (n=30)
9 (30%)

Difference between
two groups
49.3%

P-value
< 0.0001

Walters et al.5 (2016) conducted a randomized double-blind RCT for a total of sixty days
to assess the efficacy and safety of dexamethasone as a sustained-release intracanalicular
biodegradable depot for the treatment of postoperative ocular pain in patients having cataract
surgery. A total of 247 patients participated in this study across 32 different private practice sites
in the US.5 Participants were selected based on certain inclusion and exclusion criteria that can
be found as listed in Table 1. All participants were older than 18 years of age and were receiving
clear corneal cataract surgery with phacoemulsification and implantation of a PCIOL.5
Participants were randomized 2:1 where 163 participants received a sustained-release
dexamethasone depot and 83 participants received a placebo vehicle placed immediately
following surgery.5 Dexamethasone containing 0.4 mg was delivered to the ocular surface via
PEG-based hydrogel depot placed in the inferior punctum.5 The placebo consisted of a similarappearing device, but without the active ingredient of dexamethasone.5 The use of additional
anti-inflammatory drops were allowed per investigators discretion, particularly if patients were
experiencing moderate to severe pain (pain score > 4).5 Patients who received rescue medications
were deemed treatment failures after the visit in which they were prescribed the medication.5
The primary outcome measured being analyzed in this review from the Walters et al.5
(2016) study is absence of pain 8 days after receiving cataract surgery. Pain was assessed by
patients reporting their pain levels using Numeric Rating Scales where 0 represented no pain,
and 10 represented severe pain.5 Far fewer patients in the sustained-release dexamethasone group
required rescue medication compared to the placebo group.5 At day 8, 7.4% of patients in the
intervention group received rescue medication while 28.9% of patients in the placebo group
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received rescue medications (p=0.0321).5 A significantly higher amount of patients in the
intervention group compared to the placebo group reported an absence of pain 8 days after
cataract surgery.5 80.4% of the patients receiving sustained-release dexamethasone reported no
pain while 43.3% of patients receiving placebo reported no pain (Table 3).5 A p-value of <
0.0001 was reported between the intervention and control groups (Table 3).5 A 95% confidence
interval was constructed around the difference in proportions for the outcomes.5 A NNT of three
was calculated using dichotomous data from the study (Table 5). For every three cataract surgery
patients receiving a sustained-release dexamethasone depot, ocular pain for one more patient will
be prevented compared to the placebo. The reported p-value and calculated NNT indicates a
large treatment effect that is statistically significant. Values for this study are summarized below
in Tables 3 and 5.
Table 3. Occurrence of Ocular Pain in Walters et al.5 (2016) Study at day 8
Sustained-release
dexamethasone
80.4%

Placebo
43.4%

Difference between
two groups
37%

P-value
< 0.0001

The final study analyzed in this review was conducted by Tyson et al.7 as a double blind
RCT for a total of six weeks across 21 sites throughout the US to evaluate the efficacy and safety
of a sustained-release intracanalicular dexamethasone depot for the treatment of postoperative
ocular pain in cataract surgery patients. Patients were selected according to certain inclusion and
exclusion criteria that is outlined above in Table 1. A total of 438 patients were enrolled into the
study and randomized 1:1 with 216 patients in the intervention group receiving 0.4 mg of
sustained-release dexamethasone depot, and 222 patients in the control group receiving a placebo
depot placed into the inferior vertical canaliculus of the study eye immediately following cataract
removal and PCIOL placement.7 The need for additional anti-inflammatory medication was
assessed on visit days and administered to patients exhibiting an ocular pain score > 4 at
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investigators discretion.7 Patients who received rescue medication were considered treatment
failures after the visit in which they were prescribed the medication.7
Absence of pain in the study eye at Day 8 was one of the primary endpoints for this
study, and was also assessed using the same patient-reported numerical rating scale as the other
two previous studies discussed above.7 Considerably more patients reported an absence of pain
in the study eye that were in the intervention group compared to the control group at Day 8,
79.6% and 61.3%, respectively (Table 4).7 According to the study, approximately twice as many
patients in the placebo group required additional anti-inflammatory drops compared to patients
treated with sustained-release dexamethasone by the primary endpoint of day 8.7 A 95%
confidence interval was also constructed around the difference in proportions in this study.7
Dichotomous data from the study was used to compute a NNT value of six (Table 5), so for
every six cataract surgery patients receiving a sustained-release dexamethasone depot, ocular
pain for one more patient will be prevented compared to the placebo. The study reported a pvalue of < 0.0001 (Table 4).7 It can be concluded that there is a large treatment effect that is
statistically significant given the p-value and calculated NNT. Tables 4 and 5 below summarize
the values from this study.
Table 4. Occurrence of Ocular Pain in Tyson et al.7 Study at day 8
Sustained-release
dexamethasone
79.6%

Placebo
61.3%

Difference between
two groups
18.3%

Table 5. Calculations for NNT in Both Walters et al. and Tyson Studies
Study
Walters6 (2015)
Walters5 (2016)
Tyson7

EER

CER

0.793 0.310
0.804 0.434
0.796 0.613

RBI
1.56
0.853
0.299

ABI
0.483
0.37
0.183

NNT
3
3
6

P-value
< 0.0001
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DISCUSSION:
The trauma to ocular tissues that occurs during cataract surgery oftentimes leads to pain
and inflammation following the procedure. The amount of pain and inflammation a patient
experiences postoperatively directly impacts patient outcomes, satisfaction, and overall surgical
success.2,4 Modern interventions, such as the intracanalicular dexamethasone depot discussed in
this review, can significantly reduce, and potentially eliminate postoperative complications due
to pain and inflammation. The dexamethasone depot does not require any action or participation
from the patient, eliminating the noncompliance component that may adversely affect outcomes.
Furthermore, the depot optimizes the delivery of the medication, so that more of its affects and
benefits can be appreciated.4
This review evaluated the efficacy of intracanalicular dexamethasone depots for the
treatment of postoperative pain associated with cataract surgery. In all three studies, sustainedrelease intracanalicular dexamethasone was superior over placebo in reducing postoperative
ocular pain. All three studies were designed similarly, and found a statistically significant
reduction of ocular pain in the study eye that received intracanalicular dexamethasone following
cataract surgery as determined by the reported p-values. In each study, more patients in the
intervention group reported a score of zero on the Ocular Pain Assessment Scale compared to the
placebo group on post-op day 8. Additionally, in all three studies, patients receiving
intracanalicular dexamethasone required the use of additional anti-inflammatory rescue drops far
less than patients in the placebo group, indicating that the intracanalicular depot was more
effective in preventing and eradicating postoperative ocular pain early on. The studies conducted
by Walters et al.6 (2015) and Walters et al.5 (2016) both demonstrated a NNT of three, while the
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study conducted by Tyson et al.7 produced a NNT of six. Based on these NNTs, the treatment
affect was considered to be large in all three studies.
All three studies used in this review were subject to limitations in their research. In all
three studies, patients were allowed the use of systemic NSAIDs for comorbidities throughout
the duration of the study.5-7 This could have further contributed to the reduction of postoperative
pain and skewed the results in favor of the effectiveness of the intracanalicular dexamethasone
depot’s ability to reduce postoperative ocular pain. Additionally, the study conducted by Walters
et al.6 (2015) had a small sample size of 60 participants, which affects the validity and reliability
of the results from the study. Lastly, none of the studies performed worst-case analyses for
missing outcome data from participants who were lost to follow-up. This determinant makes the
studies less valid as it potentiates bias.
CONCLUSION:
All three studies utilized for this systematic review demonstrated that the use of a
sustained-release intracanalicular dexamethasone depot is an effective treatment for pain
reduction following cataract surgery. The treatment affect was determined to be large in each
study based on the calculated NNT. Additionally, the reported p-values in each study indicate
that the results are statistically significant.
Future studies should be conducted to evaluate the efficacy of intracanalicular
dexamethasone when compared to an active control such as topical steroid medications. If
possible, it may be beneficial for future investigators to take into account baseline pain tolerance
levels of participants and the circumstances that may influence their tolerance and subsequently
their self-reported pain scores. This will allow for a more accurate picture of its effectiveness in
reducing postoperative ocular pain. It may also be worth exploring the use of intracanalicular
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dexamethasone for ocular procedures other than cataract surgery as well as for ocular diseases or
conditions that require a prolonged, tapered course of steroids. Future studies may also
investigate the use of intracanalicular depots that contain other ocular medications such as
antibiotics or Glaucoma medications. While current ongoing studies of sustained-release
intracanalicular dexamethasone depots were not found during the preparation of this systematic
review, hopefully future studies will identify additional advantageous uses for intracanalicular
depots that more providers can adopt as a treatment method that is not so onerous, but instead
more auspicious for patients.
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